Jeffrey Walch
Stock Analyst at Bernstein
(2.40)
# 3,095
Out of 4,630 analysts
14
Total ratings
66.7%
Success rate
10.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeffrey Walch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RVMD Revolution Medicines | Maintained: Hold | $151 | $205.15 | -26.40% | 3 | Aug 5, 2026 | |
| BNTX BioNTech SE | Maintained: Hold | $96 | $93.67 | +2.49% | 3 | Aug 4, 2026 | |
| NBIX Neurocrine Biosciences | Maintained: Buy | $221 | $163.41 | +35.24% | 2 | Jul 30, 2026 | |
| SMMT Summit Therapeutics | Reiterated: Sell | $7.7 → $9.8 | $13.96 | -29.80% | 3 | Jun 21, 2026 | |
| JAZZ Jazz Pharmaceuticals | Reiterated: Hold | $229 | $256.56 | -10.74% | 2 | Jun 8, 2026 | |
| INCY Incyte | Initiated Coverage: Hold | $99 | $120.56 | -17.88% | 1 | May 21, 2026 |
Revolution Medicines
Aug 5, 2026
Maintained: Hold
Price Target: $151
Current: $205.15
Upside: -26.40%
BioNTech SE
Aug 4, 2026
Maintained: Hold
Price Target: $96
Current: $93.67
Upside: +2.49%
Neurocrine Biosciences
Jul 30, 2026
Maintained: Buy
Price Target: $221
Current: $163.41
Upside: +35.24%
Summit Therapeutics
Jun 21, 2026
Reiterated: Sell
Price Target: $7.7 → $9.8
Current: $13.96
Upside: -29.80%
Jazz Pharmaceuticals
Jun 8, 2026
Reiterated: Hold
Price Target: $229
Current: $256.56
Upside: -10.74%
Incyte
May 21, 2026
Initiated Coverage: Hold
Price Target: $99
Current: $120.56
Upside: -17.88%